The Association Between Plasma Fatty Acid and Cognitive Function Mediated by Inflammation in Patients With Type 2 Diabetes

Jingyi Shen

Capital Medical University

Kaifeng Li

Capital Medical University

Huiyan Yu

Capital Medical University

Bingjie Ding

Capital Medical University Affiliated Beijing Friendship Hospital

Rong Xiao

Capital Medical University

Weiwei Ma (✉ weiweima@ccmu.edu.cn)

Capital Medical University <https://orcid.org/0000-0002-1792-2760>

Research

Keywords: cognitive function, inflammatory cytokines, plasma fatty acids, diabetes, mediation model

Posted Date: June 9th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-577863/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

High fat diet may lead to systematic inflammation in patients with type 2 diabetes, which eventually result in neuronal damage and cognitive decline. However, there is a paucity of study examined whether inflammation mediated the association between diet fatty acids and cognitive function in type 2 patients with diabetes.

Methods

We evaluated the cognitive function of 372 Chinese patients with diabetes, using the mini-mental state examination (MMSE) and the montreal cognitive assessment (MoCA). Plasma fatty acids were measured by gas chromatography analysis. Inflammatory cytokines were determined by immune turbidimetric analysis and enzyme-linked immunosorbent assay (ELISA). Data was analyzed using multiple linear regression based on R program and mediation model was established by Mplus.

Results

In our study, we found the increasing of BMI may lead to cognitive impairment and induce inflammatory response. We also found higher SFAs levels in plasma were linked to cognitive decline, while higher MUFAs intake might be a protective factor for cognitive function. In addition, most PUFAs levels stood out as having increasing trends that were positively correlated to cognitive function scores, but n-6 PUFAs gave opposite results. In our study, we found higher SFAs led to higher proinflammatory factor levels. Apart from that, MUFAs, SCD-16 and SCD-18 were positively related to hs-CRP. Interestingly, we found PUFAs were negatively related to IL-10. Meanwhile, this result also indicated that C18:0 might reduce MoCA language skills scores by regulating plasma IL-10 levels.

Conclusions

Plasma fatty acids could improve or damage cognitive function by regulating IL-10, which suggested that plasma fatty acids can be evaluated as a potential indicator of cognitive function decline in 2 type diabetes.

Introduction

Diabetes, exhibited an important influence on the central nervous system, is a group of metabolic diseases in which a person has a high blood glucose levels over a prolonged period. According to the report of the International Diabetes Mellitus (IDF) [1], there were 463 million living with diabetes in 2017, and the number was predicted to rise to 700 million in 2045, which confirmed that diabetes is one of the largest global health emergencies. The situation is more serious in China. From 2015 to 2017, a nationally representative cross-sectional survey in mainland China was conducted, which showed that the weighted prevalence of diabetes was 11.2% (using the WHO criteria)[2].

The discovery that attention and memory of patients with diabetes were worse than normal individuals date back to 1922 reported by Miles [3]. There were a growing number of findings indicated that diabetes was associated with accelerated cognitive decline, mild cognitive impairment (MCI), Alzheimer's disease (AD) and dementia [4–7]. Cognitive impairment in patients with diabetes was often presented as impaired learning and memory, orientation, execution and language skill [8, 9]. According to epidemiological research, the risk to develop dementia in diabetes patients was higher than normal individuals [10, 11]. A cohort study showed that the presence of cognitive decline had a 2.5 to a 3.6-fold increase of type 2 diabetes mellitus (T2DM) patients compared with patients without diabetes[12]. This conclusion was also confirmed in animal experiments that the synaptic plasticity of obese Zucker rats reduced, accompanied with the decline in spatial learning and memory compared with lean Zucker rats.

A number of studies suggested that high fat diet could induce increased obesity [13, 14] and diabetes [15], and dietary fatty acids could regulate inflammatory responses [16–18], alleviating or aggravating cognition [19]. For instance, long chain saturated fatty acids (LCSFAs), such as palmitic acid (16:0) and stearic acids (18:0), would have adverse effects on glucose metabolism, and increase the risk of type 2 diabetes mellitus [20]. Saturated fatty acids (SFAs) could activate toll-like receptor (TLR), especially TLR 2 and TLR 4 [21], then activate nuclear factor kappa B (NF- κ B), resulting in inflammatory responses [22]. By contrast, monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) could reduce the concentration of interleukin-6 (IL-6) and tumor necrosis factor- α (TNF α), and relived inflammatory reaction [18, 23, 24]. However, the role of n-6 PUFA plays in was still controversies. Recent studies had clearly showed that inflammation is considered as the contributor to diabetic-induced neurodegeneration and cognitive impairment [25]. Moreover, the fatty acid profile in plasma, which reflected short-term effects of diets, could reduce desaturase and elongase enzyme activities, considered as biomarkers for the incident T2DM [26]. Researchers found the higher percentages of linoleic acid biomarkers of total fatty acids, the risk of T2DM lower in a study of patients, including 4347 cases, [27]. However, the role of inflammation in the progression of diabetes-associated cognitive decline remains unknown in patients with 2 type diabetes.

Therefore, we investigated whether there was a correlation between the plasma fatty acids, plasma inflammatory cytokine levels and cognitive test scores in Chinese individuals of type 2 diabetes.

Methods

Participants

Our cross-sectional study included 372 participants with diabetes, recruited among outpatients from the Department of nutrition Beijing Friendship Hospital, Capital Medical University (Beijing, China). Of all the participants, 214 (57.5%) were males and 158 (42.5%) were females: the average age was 57.09 ± 9.00 years (26-75 years). The study protocol was approved by the ethics committee of Beijing Friendship Hospital, Capital Medical University (Beijing, China) and was performed according to the ethical guidelines of the latest Declaration of Helsinki. All participants have signed an informed consent and had the right to withdraw from the study at any time for any reason. This research was approved by the Ethics Committee of the Beijing Friendship Hospital, Capital Medical University (Beijing, China) (2015-P2-090-02).

Individuals were excluded if they had: (1) severe heart, lung and kidney dysfunction or malignancy; (2) history of encephalitis, head trauma and other central nervous diseases; (3) any type of definite mental illness; (4) reading, hearing, or vision impairments; (5) losing self-caring ability.

Type 2 diabetes was diagnosed according to the World Health Organization (WHO) criteria: (1) fasting glucose ≥ 7.0 mmol/L; and/or (2) postprandial blood glucose ≥ 11.1 mmol/L; and/or (3) the subjects have been diagnosed T2DM clinically before.

Cognitive Function Assessments

All of the participants completed the Chinese versions of the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) to provide a general cognitive status [28, 29]. MMSE scale includes MMSE Orientation (maximum 10 points) MMSE Computation (maximum 5 points) MMSE Memory (maximum 6 points) MMSE Language skill (maximum 9 points) and the total score of MMSE is 30. MOCA scale includes naming ability (maximum 3 points), orientation ability (maximum 6 points), delayed recall ability (maximum 5 points), abstract thinking ability (maximum 2 points), Language skill ability (maximum 3 points), visual spatial ability (maximum 5 points) and attention ability (maximum 6 points), with a total score of 30 points.

Anthropometric and laboratory measurements

Height and weight were measured, and body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Also, we measured waist circumference and calculated waist hip ratio. Following overnight fasting, we used a vacuum tube system (Becton-Dickinson) to take a fasting peripheral blood sample (4 mL) from the antecubital vein of each participant and centrifuged the sample at 3000g for 15 minutes to obtain plasma. And the plasma samples were stored in the dark at -80°C. Fasting plasma glucose level was measured by glucose oxidase method (Olympus, Japan). The 2-hour oral glucose tolerance test (OGTT) was performed to assess insulin sensitivity. Next, by using immune turbidimetric analysis (Siemens Healthcare Diagnostics Inc), we measured each participant's serum hypersensitive C-reactive protein (hs-CRP) and C-reactive protein (CRP). Plasma insulin was measured using a chemiluminescence assay (Beckman Coulter, USA).

Fatty acids analysis

We used gas chromatography analysis was performed to determine the fatty acid compositions in plasma (ug/ml). The detailed steps were as follows. Firstly, after added 100 ul internal standard in 100 ul plasma samples, KOH methanol solution (1 ml 0.5 mol / L) was then added and the mixture was shaken in a 60 °C water bath for 10 min. Second, 13% BF₃-methanol reagent (3 mL) was added, and kept the hybrid liquid at 60 °C for 40 min, then cooled it to room temperature. Then the mixture was added in hexane (1.5 mL) and shaken with vortex for 1min immediately. After that, the mixture was added in sodium chloride (2 mL) in mixture, and centrifuged at 3000 rpm (15 min), then the upper layer was transferred to a vial for measurement. Finally, fatty acid methyl esters were analyzed using a GC-2010 gas chromatograph (Shimadzu, Japan), equipped with SP-2560 gas chromatographic column (Supelco, USA).

Measurement of Plasma Inflammatory Cytokines

We measured each participant's inflammatory cytokines (Lipopolysaccharide, IL-1 β , IL-10, NF κ Bp65 and TNF- α) according to manufacturer instructions using specialized enzyme-linked immunosorbent assay kits (Nanjing Jiancheng Bioengineering Institute, China).

Calculations

Homeostatic model assessment-IR (HOMA-IR) score was calculated using the formula (fasting insulin μ U/mL x fasting glucose mmol/L)/22.5 [30]. Quantitative sensitivity check index (QUICKI) score was calculated as follows: $1 / (\log (\text{fasting insulin } \mu\text{U/mL}) + \log (\text{fasting glucose mg/dL}))$ [31]. Desaturase activity including stearoyl-CoA desaturase (SCD), delta-5-desaturase (D5D) and delta-6-desaturase (D6D) were estimated using fatty acid product/precursor ratios as following: $\text{SCD-16} = \text{C16:1n-7/C16:0}$, $\text{SCD-18} = \text{C18:1n-7/C18:0}$, $\text{D6D} = \text{C18:3n-6/C18:2n-6}$ and $\text{D5D} = \text{C20:4n-6/C20:3n-6}$ [32].

Statistical Analysis

Data were presented as the mean and standard deviation. Multiple linear regression was used to obtain coefficients between plasma fatty acids, cognition scores, inflammation markers, biochemistry biomarker and diet balance index. Potential confounders including age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes were also included in the model. Multiple linear regression was carried out using *lm* function of base R program (version 3.5). Simple mediation model was used to evaluate indirect, direct and total effects between plasma fatty acids, inflammation markers and cognition scores. A thousand bootstrap samples were drew to estimate β coefficient indirect, direct and total effects using Mplus version 7.4 [33]. Missing values were handled using the full information maximum likelihood implemented within Mplus software. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

The relationship between adiposity indicators, biochemistry biomarkers and inflammation.

Firstly, we measured the relationship between adiposity indicators, biochemistry biomarkers and inflammation after adjusting for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. As shown in Table 1, BMI, waist circumference and waist hip ratio were negatively associated with QUICKI ($P < 0.01$; $P < 0.05$). At the same time, BMI and waist circumference both positively correlated with HOMA-IR ($P < 0.01$). In addition, Table 2 indicated that BMI and waist circumference may be linked to the increase of plasma hs-CRP and CRP level ($P < 0.01$).

Table 1
Multiple linear regression between adiposity and biochemistry biomarkers (n = 372)

	OGTT		OGTT2		Insulin		HOMA-IR		QUICKI	
	β	P	β	P	β	P	β	P	β	P
BMI	-0.024	0.779	-0.057	0.859	0.683	0.036*	0.011	0.001**	-0.003	0.003**
Waist circumference	-0.003	0.821	0.014	0.469	0.149	0.106	0.004	0.003**	-0.001	0.001**
Waist hip ratio	-0.518	0.759	6.552	0.258	13.182	0.360	0.387	0.090	-0.137	0.041*
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. OGTT, oral glucose tolerance test. HOMA-IR, homeostatic model assessment-insulin resistance. QUICKI, quantitative sensitivity check index. *Significant at $P < 0.05$. **Significant at $P < 0.01$.										

Table 2
Multiple linear regression between adiposity and inflammation (n = 372)

	IL-1 β		IL-10		NFkBp65		TNF- α		hs-CRP		CRP		LPS	
	β	P	β	P	β	P	β	P	β	P	β	P	β	P
BMI	0.003	0.672	-0.016	0.258	0.031	0.321	-0.001	0.964	0.053	0.000**	0.040	0.000**	-0.212	0.581
Waist circumference	0.000	0.844	-0.001	0.931	0.008	0.448	-0.001	0.895	0.017	0.001**	0.013	0.004**	-0.136	0.660
Waist hip ratio	0.185	0.719	-0.347	0.852	0.178	0.858	-0.200	0.832	1.029	0.426	1.248	0.225	1.897	0.612
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. IL, Interleukin. NFkB, nuclear factor kappa-B. TNF- α , tumor necrosis factor- α . hs-CRP, hypersensitive C-reactive protein. CRP, C-reactive protein. LPS, Lipopolysaccharide. *Significant at $P < 0.05$. **Significant at $P < 0.01$.														

The relationship between adiposity indicators and cognitive function score.

In this study, we did not find any significant difference in total MoCA score or total MMSE score ($P > 0.05$) (Table 3 and Table 4). However, the increasing of BMI may lead to a drop of the score of Language skill in MoCA ($P < 0.05$) (Table 4).

Table 3
Multiple linear regression between cognitive function score measured by MMSE and adiposity (n = 372)

	MMSE		MMSE Orientation		MMSE Computation		MMSE Memory		MMSE Language skill	
	β	P	β	P	β	P	β	P	β	P
BMI	-0.005	0.514	-0.015	0.069	0.004	0.995	-0.001	0.634	0.000	0.755
Waist circumference	-0.007	0.125	-0.005	0.066	-0.001	0.531	-0.001	0.323	-0.001	0.464
Waist hip ratio	-2.246	0.126	-0.590	0.322	-0.977	0.251	-0.219	0.168	0.034	0.977
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. MMSE, Mini-mental State Examination. *Significant at $P < 0.05$. **Significant at $P < 0.01$.										

Table 4
Multiple linear regression between cognitive function score measured by MoCA and adiposity (n = 372)

	MoCA		MoCA Naming		MoCA Orientation		MoCA Delayed recall		MoCA Abstract thinking		MoCA Language skill		MoCA Visual spatial ability		MoCA Attentive
	β	P	β	P	β	P	β	P	β	P	β	P	β	P	β
BMI	-0.033	0.154	0.005	0.329	-0.008	0.179	-0.015	0.274	0.002	0.900	-0.022	0.049*	0.010	0.912	-0.004
Waist circumference	-0.013	0.090	0.001	0.493	-0.002	0.208	-0.004	0.194	0.004	0.457	-0.009	0.026*	-0.001	0.515	-0.002
Waist hip ratio	1.726	0.830	0.030	0.860	-0.609	0.157	0.707	0.869	0.846	0.183	-0.308	0.611	1.788	0.199	-0.872
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. MoCA, Montreal Cognitive Assessment. *Significant at $P < 0.05$. **Significant at $P < 0.01$.															

The relationship between plasma fatty acids, biochemistry biomarkers and inflammation.

In our study, we found different plasma fatty acid had different effects on inflammatory responses and biochemistry biomarkers (Table 5 and Table 6). There was positive relationship between C14:0 level and OGTT, OGTT2 and HOMA-IR ($P < 0.05$), while it also had a negative relationship with QUICKI ($P < 0.01$). C16:0 level was positively correlated with HOMA-IR ($P < 0.05$), while it was negatively related to QUICKI ($P < 0.05$). C17:0 level was negatively correlated with insulin ($P < 0.05$). C17:0 level was negatively correlated with OGTT2 ($P < 0.05$). MUFA and C18:1n-9 levels were both positively correlated with OGTT and OGTT2 ($P < 0.01$). PUFA was negatively correlated with HOMA-IR ($P < 0.01$) and positively correlated with QUICKI ($P < 0.01$), as well as n-6 PUFA and C18:2n-6 levels. In addition, C18:3n-3 level was positively correlated with OGTT and OGTT2 ($P < 0.05$), and C22:6n-3 level was positively correlated with QUICKI ($P < 0.05$). C20:4n-6 level was negatively correlated with OGTT ($P < 0.05$). SCD-18 was positively correlated with OGTT and OGTT2 ($P < 0.01$). (Table 5)

Table 5
Multiple linear regression between plasma fatty acids (%) and biochemistry biomarkers (n = 372)

	OGTT		OGTT2		Insulin		HOMA-IR		QUICKI	
	β	P	β	P	β	P	β	P	β	P
SFA	-0.015	0.862	-0.102	0.249	0.099	0.980	0.002	0.810	0.000	0.903
C14:0	2.387	0.011*	2.107	0.041*	-3.189	0.833	0.183	0.007**	-0.069	0.000**
C15:0	1.266	0.724	4.655	0.720	-24.863	0.445	-0.328	0.377	0.036	0.686
C16:0	0.061	0.395	-0.085	0.181	0.609	0.358	0.014	0.020*	-0.004	0.036*
C17:0	3.012	0.378	11.447	0.296	-83.194	0.010*	-0.231	0.325	-0.096	0.463
C18:0	-0.073	0.186	-0.165	0.036*	0.483	0.359	0.008	0.189	-0.002	0.396
MUFA	0.174	0.010*	0.279	0.009**	-0.631	0.647	0.000	0.253	-0.001	0.123
C16:1	0.387	0.353	-0.143	0.918	-2.079	0.646	0.022	0.245	-0.009	0.155
C18:1n-9	0.174	0.010*	0.279	0.009**	-0.631	0.647	0.000	0.253	-0.001	0.123
PUFA	-0.087	0.139	-0.013	0.345	-0.087	0.568	-0.010	0.008**	0.003	0.001**
n-3 PUFA	-0.282	0.396	0.399	0.304	-0.440	0.851	-0.019	0.389	0.007	0.326
C18:3n-3	1.564	0.031*	3.696	0.002**	-2.626	0.545	0.023	0.587	-0.017	0.237
C20:5n-3	-0.425	0.743	1.594	0.159	-5.509	0.532	-0.013	0.788	-0.002	0.977
C22:6n-3	-0.527	0.081	0.266	0.400	-0.736	0.541	-0.042	0.079	0.014	0.037*
n-6 PUFA	-0.069	0.222	-0.012	0.542	-0.024	0.549	-0.009	0.006**	0.003	0.000**
C18:2n-6	-0.018	0.683	0.007	0.998	-0.338	0.245	-0.011	0.000**	0.003	0.001**
C18:3n-6	-2.195	0.181	-1.721	0.991	3.449	0.373	-0.017	0.656	0.011	0.953
C20:3n-6	-0.982	0.139	-1.410	0.675	0.618	0.810	0.021	0.335	-0.002	0.433
C20:4n-6	-0.171	0.045*	-0.121	0.826	0.709	0.400	0.001	0.889	0.000	0.977
SCD-16	9.091	0.467	-2.213	0.694	-72.070	0.554	0.160	0.436	-0.117	0.287
SCD-18	0.847	0.008**	1.442	0.004**	-2.278	0.605	-0.006	0.641	-0.003	0.353
D6D	-45.842	0.275	-42.343	0.914	138.495	0.256	1.921	0.207	-0.375	0.310
D5D	0.031	0.607	0.081	0.430	0.098	0.949	0.000	0.425	0.000	0.582

Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. SFA, saturated fatty acids. MUFA, monounsaturated fatty acids. PUFA, polyunsaturated fatty acids. SCD: stearyl-CoA desaturase; D5D: delta-5-desaturase; D6D: delta-6-desaturase. OGTT, oral glucose tolerance test. HOMA-IR, homeostatic model assessment-insulin resistance. QUICKI, quantitative sensitivity check index. *Significant at $P < 0.05$. **Significant at $P < 0.01$.

Table 6
Multiple linear regression between plasma fatty acids (%) and inflammation (n = 372)

	IL-1 β		IL-10		NF κ Bp65		TNF- α		hs-CRP		CRP		LPS	
	β	P	β	P	β	P	β	P	β	P	β	P	β	P
SFA	-0.002	0.857	0.020	0.207	0.051	0.186	0.015	0.370	-0.016	0.073	-0.014	0.150	1.136	0.043*
C14:0	-0.316	0.152	0.180	0.822	0.325	0.514	-0.020	0.991	-0.059	0.226	-0.121	0.443	-5.514	0.318
C15:0	-0.571	0.520	-0.334	0.810	3.774	0.326	-0.587	0.851	-0.248	0.575	0.274	0.958	-52.829	0.433
C16:0	-0.017	0.230	0.058	0.004**	0.002	0.700	-0.003	0.881	-0.003	0.847	0.000	0.966	1.461	0.014*
C17:0	-0.174	0.629	0.448	0.853	4.309	0.131	1.476	0.198	-1.742	0.007**	-1.846	0.005**	31.483	0.218
C18:0	-0.007	0.503	0.040	0.012*	0.034	0.298	0.002	0.759	-0.019	0.019*	-0.020	0.020*	1.686	0.000**
MUFA	0.011	0.342	0.003	0.870	0.037	0.488	0.019	0.384	0.017	0.016*	0.008	0.109	-1.070	0.064
C16:1	-0.117	0.179	-0.043	0.664	-0.090	0.742	0.017	0.870	0.040	0.046*	0.052	0.065	-5.025	0.025*
C18:1n-9	0.011	0.342	0.003	0.870	0.037	0.488	0.019	0.384	0.017	0.016*	0.008	0.109	-1.070	0.064
PUFA	0.011	0.447	-0.034	0.071	-0.008	0.654	-0.011	0.475	-0.003	0.590	0.012	0.534	-0.547	0.206
n-3PUFA	-0.038	0.314	-0.005	0.907	-0.181	0.303	-0.165	0.028*	-0.117	0.034*	-0.088	0.078	-3.916	0.116
C18:3n-3	-0.073	0.543	-0.385	0.042*	-0.270	0.569	-0.218	0.272	-0.114	0.993	-0.100	0.858	-16.313	0.007**
C20:5n-3	-0.075	0.611	-0.198	0.718	-0.725	0.366	-0.359	0.241	-0.545	0.009**	-0.391	0.033*	-17.344	0.119
C22:6n-3	-0.049	0.325	0.012	0.941	-0.185	0.378	-0.099	0.233	-0.075	0.385	-0.049	0.564	-0.610	0.817
n-6PUFA	0.011	0.375	-0.036	0.037*	-0.016	0.598	-0.006	0.732	0.003	0.631	0.009	0.778	-0.392	0.407
C18:2n-6	0.005	0.753	-0.033	0.005**	-0.019	0.252	-0.013	0.161	0.004	0.618	0.005	0.839	-0.734	0.049*
C18:3n-6	-0.290	0.548	-0.902	0.044*	-1.085	0.510	0.189	0.648	-0.377	0.970	-0.016	0.346	-14.444	0.201
C20:3n-6	-0.189	0.200	-0.261	0.069	-0.153	0.986	-0.059	0.739	0.036	0.065	-0.099	0.356	-1.580	0.413
C20:4n-6	0.024	0.127	-0.032	0.259	-0.059	0.518	0.034	0.169	0.014	0.359	0.024	0.139	-0.824	0.265
SCD-16	-2.884	0.294	-2.363	0.415	-0.403	0.958	0.974	0.770	1.572	0.020*	1.695	0.038*	-188.223	0.006**
SCD-18	0.069	0.282	-0.091	0.367	0.112	0.752	0.019	0.900	0.117	0.012*	0.083	0.054	-9.615	0.001**
D6D	-9.942	0.449	-16.988	0.172	-32.305	0.464	8.422	0.515	-10.779	0.993	-2.775	0.483	-346.911	0.277
D5D	0.015	0.199	-0.004	0.982	-0.006	0.685	0.010	0.512	0.000	0.211	0.012	0.881	-0.138	0.979
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. SFA, saturated fatty acids. MUFA, monounsaturated fatty acids. PUFA, polyunsaturated fatty acids. IL, Interleukin. NF κ B, nuclear factor kappa-B. TNF- α , tumor necrosis factor- α . hs-CRP, hypersensitive C-reactive protein. CRP, C-reactive protein. LPS, Lipopolysaccharide. *Significant at $P < 0.05$. **Significant at $P < 0.01$.														

As shown in Table 6, SFA level was positively correlated with LPS ($P < 0.05$). C16:0 and C18:0 levels were positively correlated with IL-10 and LPS ($P < 0.05$), while C18:0 and C17:0 levels were both negatively correlated with hs-CRP and CRP levels in plasma ($P < 0.05$). MUFA, C16:1 and C18:1n-9 levels were positively associated with hs-CRP ($P < 0.05$), but negatively correlated with LPS level. n-3 PUFA level was negatively correlated with TNF- α and hs-CRP levels ($P < 0.05$), and C20:5n-3 level was correlated with hs-CRP and CRP levels ($P < 0.05$). C18:3n-3, n-6 PUFA, C18:2n-6 and C18:3n-6 levels were negatively correlated with IL-10 level. At the same time, C18:3n-3 and C18:2n-6 levels were respectively and negatively correlated with LPS level. SCD-16 and SCD-18 both had a positive relationship with hs-CRP level ($P < 0.05$), and a negative relationship with LPS level ($P < 0.01$). What's more, SCD-16 also had a positive relationship with CRP level.

The relationship between plasma fatty acids and cognitive function score.

As shown in Table 7, we found significant difference in total MMSE score and MMSE orientation for SFA, C16:0 and C18:0 levels ($P < 0.05$). What's more, in our study, C18:0 level was negatively associated with MMSE orientation ($P < 0.05$). In addition, the level of plasma of SCD-18 higher, total MMSE score higher and accompanied with the orientation ability increasing in participants. However, the result showed greater D5D level was associated with higher MMSE computation scores ($P < 0.05$). As shown in Table 8, SFA, C16:0 and C18:0 levels were negatively associated with MoCA orientation and Language skill, and

the growth of C18:0 level in plasma accompanied by a lower MoCA score. In addition, the data exhibited in Table 8 suggested MUFA, C18:1n-9 and SCD-18 levels were associated with increased of total MoCA and MoCA delayed recall scores ($P < 0.05$). What's more, C18:3n-3 and C20:3n-6 levels were both negatively associated with MoCA naming scores ($P < 0.05$), while PUFA and C18:2n-6 both had a positive relationship with MoCA orientation scores ($P < 0.05$). C16:1, C18:3n-6, C20:3n-6, SCD-16, D6D levels had a positive relationship with MoCA abstract thinking scores. On the contrast, the relationship between D5D and MoCA abstract thinking scores was negatively. Moreover, C18:2n-6 and SCD-18 levels both were positively associated with MoCA Language skill scores. Finally, higher MoCA attention scores were accompanied by a increase of C18:3n-6 level and a decrease of D5D level in plasma ($P < 0.05$).

Table 7
Multiple linear regression between plasma fatty acids (%) and cognitive function score measured by MMSE (n = 372)

	MMSE		MMSE Orientation		MMSE Computation		MMSE Memory		MMSE Language skill	
	β	P	β	P	β	P	β	P	β	P
SFA	-0.064	0.002**	-0.019	0.010*	-0.014	0.271	0.001	0.751	-0.018	
C14:0	-0.885	0.161	-0.085	0.568	-0.350	0.383	0.013	0.860	-0.260	
C15:0	1.991	0.506	0.603	0.435	-1.319	0.473	0.069	0.908	0.957	
C16:0	-0.057	0.107	-0.035	0.018*	0.008	0.870	0.001	0.933	-0.015	
C17:0	0.194	0.371	0.894	0.125	0.582	0.492	-0.080	0.807	-0.790	
C18:0	-0.052	0.014*	-0.028	0.008**	-0.008	0.385	0.002	0.675	-0.003	
MUFA	0.015	0.299	0.021	0.096	0.012	0.438	-0.003	0.386	-0.005	
C16:1	-0.309	0.137	0.031	0.738	-0.116	0.430	-0.007	0.754	-0.141	
C18:1n-9	0.015	0.299	0.021	0.096	0.012	0.438	-0.003	0.386	-0.005	
PUFA	0.057	0.082	0.013	0.140	0.012	0.626	0.001	0.763	0.014	
n-3 PUFA	0.154	0.094	-0.031	0.967	0.088	0.204	-0.004	0.936	0.037	
C18:3n-3	-0.061	0.550	0.026	0.735	0.132	0.372	-0.035	0.454	-0.200	
C20:5n-3	0.194	0.827	-0.054	0.920	0.203	0.674	-0.008	0.932	-0.117	
C22:6n-3	0.040	0.347	-0.041	0.732	0.050	0.417	0.000	0.844	0.029	
n-6 PUFA	0.050	0.148	0.012	0.156	0.004	0.904	0.001	0.708	0.014	
C18:2n-6	0.030	0.066	0.010	0.157	-0.011	0.627	0.000	0.737	0.008	
C18:3n-6	-0.410	0.118	0.541	0.471	-0.493	0.155	0.047	0.673	-0.189	
C20:3n-6	0.128	0.584	0.198	0.569	-0.349	0.085	-0.008	0.910	0.219	
C20:4n-6	0.089	0.373	0.042	0.084	0.049	0.218	0.000	0.949	0.018	
SCD-16	-7.385	0.224	1.824	0.471	-4.110	0.331	-0.226	0.745	-3.488	
SCD-18	0.266	0.033*	0.118	0.038*	0.124	0.163	-0.004	0.772	0.031	
D6D	-20.981	0.056	14.523	0.593	-7.201	0.324	0.715	0.762	-12.021	
D5D	0.022	0.362	0.002	0.506	0.041	0.032*	-0.001	0.847	-0.013	
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. SFA, saturated fatty acids. MUFA, monounsaturated fatty acids. PUFA, polyunsaturated fatty acids. SCD: stearyl-CoA desaturase; D5D: delta-5-desaturase; D6D: delta-6-desaturase. MMSE, Mini-mental State Examination. *Significant at $P < 0.05$. **Significant at $P < 0.01$.										

Table 8
Multiple linear regression between plasma fatty acids (%) and cognitive function score measured by MoCA (n = 372)

	MoCA		MoCA Naming		MoCA Orientation		MoCA Delayed recall		MoCA Abstract thinking		MoCA Language skill		MoCA Visual spatial ability		MoCA
	β	P	β	P	β	P	β	P	β	P	β	P	β	P	β
SFA	-0.039	0.146	0.002	0.297	-0.013	0.031*	0.014	0.682	0.011	0.769	-0.037	0.003**	-0.009	0.294	-0.001
C14:0	-0.375	0.554	0.010	0.704	-0.166	0.324	0.257	0.667	-0.277	0.193	-0.480	0.083	0.323	0.460	-0.001
C15:0	1.309	0.811	0.154	0.643	0.724	0.338	-0.620	0.857	-0.523	0.787	-1.022	0.660	1.722	0.570	1.000
C16:0	0.002	0.840	0.002	0.481	-0.032	0.003**	0.030	0.360	0.017	0.309	-0.044	0.020*	0.033	0.405	-0.001
C17:0	0.443	0.394	-0.198	0.402	-0.061	0.850	2.815	0.061	-1.048	0.590	0.366	0.508	-0.169	0.765	-0.001
C18:0	-0.075	0.030*	-0.002	0.596	-0.022	0.004**	-0.004	0.585	0.012	0.634	-0.052	0.000**	-0.002	0.379	-0.001
MUFA	0.126	0.020*	0.003	0.456	0.016	0.090	0.066	0.034*	-0.007	0.802	0.034	0.100	0.023	0.138	-0.001
C16:1	-0.118	0.662	-0.015	0.752	0.001	0.934	-0.060	0.640	-0.154	0.036*	0.053	0.771	0.052	0.564	-0.001
C18:1n-7	0.126	0.020*	0.003	0.456	0.016	0.090	0.066	0.034*	-0.007	0.802	0.034	0.100	0.023	0.138	-0.001
PUFA	0.005	0.970	-0.002	0.250	0.016	0.028*	0.003	0.885	-0.012	0.279	0.011	0.553	-0.007	0.773	-0.001
n-3 PUFA	0.049	0.486	0.007	0.655	-0.067	0.293	0.050	0.448	-0.071	0.320	0.068	0.171	0.017	0.675	0.000
C18:3n-3	-1.012	0.609	-0.086	0.011*	0.032	0.612	-0.364	0.593	-0.100	0.870	-0.015	0.772	-0.598	0.153	0.000
C20:5n-3	0.290	0.871	0.050	0.389	-0.068	0.865	-0.210	0.627	-0.105	0.581	0.275	0.251	0.298	0.599	0.000
C22:6n-3	-0.045	0.571	0.025	0.276	-0.085	0.162	0.091	0.233	-0.072	0.334	0.083	0.129	-0.056	0.995	0.000
n-6 PUFA	0.007	0.960	0.000	0.747	0.014	0.056	0.001	0.976	-0.005	0.590	0.012	0.488	-0.010	0.581	-0.001
C18:2n-6	-0.019	0.742	-0.001	0.559	0.012	0.040*	-0.031	0.225	-0.004	0.946	0.024	0.010*	-0.020	0.456	0.000
C18:3n-6	0.306	0.249	-0.016	0.881	0.128	0.906	0.290	0.761	-0.927	0.001**	0.842	0.482	0.097	0.525	-0.001
C20:3n-6	-0.207	0.112	-0.059	0.028*	0.144	0.517	-0.133	0.380	-0.288	0.003**	0.047	0.571	0.083	0.770	-0.001
C20:4n-6	0.115	0.673	-0.005	0.514	0.036	0.050	-0.001	0.703	0.011	0.819	0.027	0.554	0.003	0.797	0.000
SCD-16	-3.830	0.606	-0.563	0.639	0.752	0.612	-1.721	0.625	-5.411	0.012*	2.370	0.597	0.978	0.650	-1.000
SCD-18	0.718	0.005**	0.018	0.365	0.072	0.069	0.268	0.047*	-0.061	0.918	0.272	0.004**	0.129	0.112	0.000
D6D	18.230	0.367	-0.478	0.924	3.491	0.796	6.005	0.694	-21.470	0.004**	22.931	0.440	6.714	0.749	-0.001
D5D	0.045	0.203	0.004	0.105	0.008	0.214	-0.004	0.984	0.023	0.037*	0.015	0.182	-0.008	0.868	0.000

Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. SCD: stearoyl-CoA desaturase; D5D: delta-5-desaturase; D6D: delta-6-desaturase. MoCA, Montreal Cognitive Assessment. *Significant at $P < 0.05$. **Significant at $P < 0.01$.

The relationship between cognitive function score, biochemistry biomarkers and inflammation.

To be verify our hypothesis, we estimated the relationship between cognitive function score, biochemistry biomarkers and inflammation (Table 9 and Table 10). In generally, elevated plasma levels of inflammation-related cytokines were strongly associated with cognitive function score decline, especially IL-1 β , IL-10, NF κ Bp65, OGTT2, insulin, and HOMA-IR.

Table 9
Multiple linear regression between cognitive function score measured by MMSE, inflammation and biochemistry biomarkers (n = 372)

	MMSE		MMSE Orientation		MMSE Computation		MMSE Memory		MMSE Language skill	
	β	P	β	P	β	P	β	P	β	P
IL-1 β	-0.423	0.008**	-0.166	0.007**	-0.047	0.561	0.009	0.598	-0.058	0.274
IL-10	0.010	0.940	-0.005	0.836	0.102	0.236	0.002	0.918	-0.037	0.534
NF κ Bp65	-0.124	0.002**	-0.026	0.070	-0.066	0.012*	0.004	0.496	0.001	0.728
TNF- α	-0.061	0.493	0.021	0.568	-0.029	0.607	-0.004	0.738	-0.055	0.252
hs-CRP	0.188	0.405	0.012	0.689	-0.008	0.995	-0.006	0.744	0.099	0.316
CRP	0.142	0.738	0.015	0.672	0.036	0.714	-0.001	0.952	0.058	0.832
LPS	0.000	0.873	0.000	0.825	0.000	0.892	0.000	0.841	0.001	0.258
OGTT	0.007	0.928	-0.010	0.565	0.024	0.392	-0.006	0.118	0.002	0.921
OGTT2	0.016	0.607	-0.003	0.420	0.011	0.791	-0.001	0.764	0.008	0.856
Insulin	-0.004	0.105	-0.002	0.054	0.000	0.810	0.000	0.945	0.000	0.744
HOMA-IR	0.035	0.651	-0.019	0.510	0.312	0.396	-0.012	0.621	0.080	0.823
QUICKI	-1.555	0.668	-0.962	0.311	-1.489	0.214	0.096	0.489	-0.301	0.792
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. IL, Interleukin. NF κ B, nuclear factor kappa-B. TNF- α , tumor necrosis factor- α . hs-CRP, hypersensitive C-reactive protein. CRP, C-reactive protein. OGTT, oral glucose tolerance test. HOMA-IR, homeostatic model assessment-insulin resistance. QUICKI, quantitative sensitivity check index. LPS, Lipopolysaccharide. MMSE, Mini-mental State Examination. *Significant at $P < 0.05$. **Significant at $P < 0.01$.										

Table 10
Multiple linear regression between cognitive function score measured by MoCA, inflammation and biochemistry biomarkers (n = 372)

	MoCA		MoCA Naming		MoCA Orientation		MoCA Delayed recall		MoCA Abstract thinking		MoCA Language skill		MoCA Visual spatial ability		MoCA A
	β	P	β	P	β	P	β	P	β	P	β	P	β	P	β
IL-1 β	-0.412	0.101	0.024	0.310	-0.061	0.173	-0.223	0.070	0.068	0.533	-0.050	0.446	-0.043	0.659	-0.105
IL-10	-0.114	0.753	0.005	0.717	0.001	0.806	-0.026	0.774	0.036	0.390	-0.156	0.035*	0.069	0.368	-0.056
NF κ Bp65	-0.172	0.008**	0.008	0.149	-0.009	0.282	-0.055	0.088	0.007	0.924	-0.036	0.064	-0.019	0.328	-0.053
TNF- α	-0.207	0.274	0.012	0.371	0.019	0.628	-0.069	0.499	0.022	0.790	-0.097	0.127	-0.025	0.604	-0.068
hs-CRP	0.054	0.738	0.024	0.292	-0.007	0.627	-0.096	0.332	0.055	0.706	0.004	0.546	0.016	0.895	0.009
CRP	0.164	0.769	0.015	0.429	-0.003	0.626	-0.040	0.474	0.084	0.508	0.117	0.651	-0.126	0.208	0.038
LPS	0.005	0.532	0.000	0.354	0.000	0.720	0.001	0.769	0.001	0.409	-0.002	0.375	0.006	0.058	0.001
OGTT	-0.013	0.683	0.006	0.391	-0.005	0.735	0.009	0.780	-0.001	0.987	-0.020	0.283	0.016	0.821	-0.001
OGTT2	0.026	0.359	0.003	0.673	-0.007	0.170	0.033	0.419	0.007	0.875	-0.025	0.012*	0.026	0.582	-0.001
Insulin	-0.017	0.009**	0.000	0.954	-0.003	0.022*	-0.002	0.269	-0.002	0.469	-0.004	0.033*	-0.006	0.073	-0.003
HOMA-IR	-0.980	0.094	-0.039	0.770	-0.010	0.648	0.028	0.648	-0.102	0.654	-0.412	0.036*	-0.294	0.365	-0.098
QUICKI	1.209	0.360	0.155	0.693	-0.558	0.458	-0.857	0.864	0.013	0.941	1.409	0.053	1.149	0.345	-0.346
Multiple linear regression adjusted for age, gender, energy, BMI, education, smoking habit, alcohol and energy intakes. IL, Interleukin. NF κ B, nuclear factor kappa-B. TNF- α , tumor necrosis factor- α . hs-CRP, hypersensitive C-reactive protein. CRP, C-reactive protein. OGTT, oral glucose tolerance test. HOMA-IR, homeostatic model assessment-insulin resistance. QUICKI, quantitative sensitivity check index. LPS, Lipopolysaccharide. MoCA, Montreal Cognitive Assessment. *Significant at $P < 0.05$. **Significant at $P < 0.01$.															

Summary Of Mediation Models

All the results above showed that certain plasma fatty acids may be the protective or risk factors of the cognitive function in those living with type 2 diabetes in our study, and these effects might be achieved by regulating inflammatory response. At the same time, IL-10 was significantly related to plasma fatty acids (C16:0, C18:0, C18:2n-6) and also to MoCA Language skill score. Similarly, HOMA-IR was significantly related to C18:0, C18:2n-6 and MoCA Language skill score. After adjusting for age, gender, energy intakes, BMI, education, smoking and drinking habits, we use Mplus version 7.4 to estimate mediation effect. The result was shown in Table 11. Because the total effect was not significant, C16:0 might affect cognitive function by other biological pathway instead of regulating IL-10 levels. However, C18:0 might reduce MoCA Language skills scores by regulating plasma IL-10 levels completely.

Table 11
Summary of mediation models when mediator is IL-10

Summary of mediation models when mediator is IL-10								
Independent variable	Mediator	Dependent variable	Direct effects	P	Indirect effects	P	Total effects	P
C16:0	IL-10	MoCA Language skill	-0.033	0.115	-0.007	0.142	-0.04	0.053
C18:0			-0.046	0.007	-0.005	0.182	-0.05	0.003
C18:2n-6			0.024	0.054	0.003	0.168	0.027	0.029
Simple mediation analysis adjusted for age, gender, energy intakes, BMI, education, smoking and drinking habits. IL, Interleukin. MoCA, Montreal Cognitive Assessment. * means $P<0.05$, ** means $P<0.01$.								

Discussion

Although some previous studies suggested that diabetes-related inflammation may be one of the biological pathways linked fatty acids and cognitive decline[34], definite evidence also need to be verified. Thus, the mediation model was established to examine whether inflammation statistically mediated the relationship between plasma fatty acids and cognition function, which was evaluated by MMSE and MoCA scale.

Previous studies pointed that overweight and obesity were linked to insulin resistance[35], which was frequently associated with inflammation[36]. On the contrary, those who were obesity might become insensitive to insulin[37]. In the present study, we observed similar results. We found a higher HOMA-IR, hs-CRP and CRP levels were related to higher BMI and waist circumference, while QUICKI was negatively related to the markers of obesity. Early studies also revealed waist circumference was significantly related to high prevalence of cognitive dysfunction, which is independent of other related metabolic diseases and lifestyle risk factor, including smoking and drinking[38]. Based on neuroimaging findings, those who were obesity showed damaged brain structure (brain volume loss and brain atrophy of the grey matter) [39, 40], which indeed lead to cognitive impairment [41]. Similarly, in our study, BMI was negatively correlated with MoCA Language skills scores and the increasing of waist circumference may lead to a drop of the score of language skills in MoCA. These findings suggested that inflammation from obesity might cause cognitive decline in T2DM.

Most previous studies indicated high SFA may be a risk factor of learning and memory ability, while MUFA and PUFA had protective effects of age-related cognitive decline[42, 43]. Yu *et al* found high SFAs diet resulted in obesity in mice and subsequently damaged the function of spatial learning and memory in mice[44]. In a follow-up study, a conclusion was drawn by using structured interviews, which indicated high intake of dietary SFAs could aggravate clinical symptoms in AD patients and increase the risk of AD[45]. Our study gave similar conclusion that SFAs might destroy the orientation and language skills of patients with T2DM. In a prospective population-based study on elder participants with a typical Mediterranean diet, high PUFA and MUFA intakes seemed might be protective measure to against age-related cognitive decline[46]. n-3 PUFA could improve cognitive function[47], while the effect on cognitive function of n-6 PUFA still remained controversial[48, 49]. Some previous studies showed n-6 PUFA enhanced the tissue inflammatory response[50], and increased the risk of cognitive impairment[51], whereas another study pointed that difference may result from the n-6/n-3 PUFA ratio in diet[52, 53]. Our result was consistent with previous studies. Higher SFAs levels in plasma were linked to cognitive decline (SFA, C16:0 and C18:0), and higher MUFAs intake might be a protective factor for cognitive function, except C16:1. In addition, although PUFA and C18:2n-6 had a positive association with MoCA Orientation, and most PUFAs levels stood out as having increasing trends that were positively correlated to cognitive function scores, the C18:3n-3, C18:3n-6 and C20:3n-6 gave opposite results. However, we didn't find significant difference between cognition function and n-3 PUFA. This may due to the fact that plasma fatty acids reflect more short-term intake of dietary fatty acids. In addition, ratio of n-3: n-6 fatty acids might affect the PUFAs metabolism. As reported, the activity of SCD, D5D, D6D was associated with metabolic-related diseases[54]. In this study, similarly, SCD-18 and D5D had positive relationships with cognitive function scores, instead, SCD-16 and D6D showed opposite results. SCD converted a portion of 16:0 into palmitoleic (16:1) and 18:0 into oleic acid (18:1), which might contribute to the more abundant of MUFA species. Arachidonic acid (C20:4n-6) and g-linoleate (C18:3n-6) were derived from g-arachidonic acid (C20:3n-6) and linoleate (C18:2n-6) through desaturation (D6D and D5D) and elongation[55]. So the activity of D5D and D6D could change the proportion of n-6 PUFAs. Previous studies showed that increasing SCD-1 activity was associated AD[56]. Moreover, previous studies indicated higher D5D was associated with better insulin sensitive, while lower D6D activity led to lower risk of insulin resistance[56], which might result in different effect on cognitive function. And the genotype of related genes might affect the metabolic efficiency of PUFAs and desaturase activity, such as FADS1, which encoded D5D[57].

Several researches existed that inflammation is involved in the development and/or progression of T2DM[58, 59]. And the inflammatory response could be impacted by diet fatty acids. High fat diet may reduce synaptic plasticity and destroy insulin signaling/glucose homeostasis, which activate the innate immune system, including increased inflammatory cytokines, such as IL-6, IL-1 β , TNF α [60]. In our study, we found higher SFAs led to higher HOMA-IR and higher LPS levels, and positive correlation trends had been found between SFAs and NF κ Bp65, TNF- α . Another study also showed that high SFA diet led to activated protein kinase (AMPK), TLR4 and higher HOMA-IR values [61]. SFA was reported that contributed to inflammatory response and higher levels of plasma inflammatory factors (e.g., IL-1 β , IL-6) [21, 62]. While treating the high fat diet fed mice with palmitoleic acid or oleic acid daily by oral gavage decreased the expression of IL-1 β and IL-12 in PPAR- α -knockout (KO) mice[24]. There was another study showed that n-3 PUFA supplementation could reduce IL-6 and TNF- α production in T2DM [63]. In this research, MUFAs, SCD-16 and SCD-18 were positively related to hs-CRP. That might due to the proportion of MUFA in the diet and diet pattern. In addition, IL-10 has been pointed out to be associated with the occurrence of AD as an anti-inflammatory mediator[64]. IL-10 could reduce synthesis of pro-inflammatory and inflammatory responses in the brain as a suppressor so that it could negatively control the immunomodulatory action of IL-1, IL-2, IL-6, IL-8, IL-12 and TNF- α [65], and the effects may have been considerably influenced by single nucleotide polymorphisms[66]. Interestingly, we found PUFAs were negatively related to IL-10, which might result from the ratio of n-3: n-6 fatty acids. In an animal experiment, researchers found that compared the subjects fed with Mediterranean diet (balanced n-6/n-3 PUFA ratio), the rats fed with Western diet (high n-6/n-3 PUFA ratio) showed lower IL-10 levels and accompanied by memory deficits[67]. Furthermore, the Single Nucleotide Polymorphisms (SNP) of IL-10

should be noted. In addition, higher PUFAs led to lower inflammatory cytokines levels, such as hs-CRP, CRP and LPS. This finding provided evidence that the intake of PUFAs could reduce inflammatory response. These increased inflammatory cytokines could induce activation microglia and result in neuroinflammation[68], accompanied by disrupt neurogenesis and brain structures[69]. For example, in a case-control study, the serum levels of hs-CRP, IL-6 and TNF- α in T2DM subjects with MCI were significantly higher than type 2 diabetic patients[70]. Consistently, we showed that higher IL-1 β , IL-10 and NF- κ Bp65 levels were related to lower cognitive function scores.

In order to verify the effects of fatty acids on inflammation and cognition function, the mediating effect analysis was conducted. There was a significant negative relationship between IL-10 and MoCA language skill in our study. This study found C18:0 could reduce MoCA language skills scores by regulating plasma IL-10 levels. More specifically, through decreasing IL-10 levels of patients with diabetes, higher C18:0 might damage their language skill, which was evaluated by MoCA. In the past few years, some researchers found fatty acids in diet could change IL-10 levels. Supplementation with n-3 PUFA can reduce the inflammatory response in rat, increase levels of IL-10, but decreasing levels of TNF- α , IL-6, IL-1 β , and IL-17[71] and higher n-6: n-3 fatty acids ratio might reduce IL-10 levels and lead to cognitive impairment[35]. Some evidence was given to prove IL-10 could improve spatial cognitive decline in transgenic AD mice[72]. In a cross-sectional analysis, however, higher IL-10 levels were associated with greater odds of MCI diagnosis[73]. Though we found the mediating effect of C18:0 on IL-10 and MoCA language skills, more researches were still needed to support this finding.

There were still some limitations in our study. We need expand the sample size and choose different sources of participants instead of limited to hospital patients. Apart from this, erythrocyte membrane fatty acid components of T2DM should be tested to evaluate the dietary fatty acid intake.

In conclusion, our study supports the hypothesis that plasma fatty acid can influence cognitive function by regulating inflammation, which suggested that plasma fatty acids can be evaluated as a potential indicator of cognitive function decline.

Declarations

Acknowledgments

The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting, and editing of the paper and its final contents.

Funding

This work was supported by grants from the National Natural Science Foundation of China. This work was supported by grants from the National Natural Science Foundation of China (NO.81773406).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

This research was approved by the Ethics Committee of the Beijing Friendship Hospital, Capital Medical University (Beijing, China) (2015-P2-090-02).

Consent for publication

Not applicable

Competing interests

The authors declare no conflict of interest.

Authors' information

Jingyi Shen, Kaifeng Li and Huiyan Yu contributed equally to this work

Affiliations

Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, 100069, China

Jingyi Shen

Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, 100069, China

Kaifeng Li

Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, 100050, China

Huiyan Yu

Department of Clinical Nutrition, Beijing Friendship Hospital, Capital Medical University, Beijing, 100069, China

Bingjie Ding

Rong Xiao

Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, 100069, China

Weiwei Ma

Corresponding authors

Correspondence to Weiwei Ma.

Authors' contributions

Jingyi Shen: Formal analysis, Writing - original draft. Kaifeng Li: Performed the statistical analyses. Huiyan Yu: Review & editing. Bingjie Ding: Carried out major experiments. Rong Xiao: Supervision. Weiwei Ma: Project administration. All authors have read and approved the final manuscript.

References

1. Mellitus, I. D. (Producer). Retrieved from <https://www.diabetesatlas.org/en/>
2. Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H, Shi B, Sun H, Ba J, Chen B, et al: Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. *Bmj* 2020, 369:m997.
3. MILES WR, ROOT HF: Psychologic tests applied to diabetic patients. *Archives of Internal Medicine* 1922, 30:767-777.
4. Nunley KA, Rosano C, Ryan CM, Jennings JR, Aizenstein HJ, Zgibor JC, Costacou T, Boudreau RM, Miller R, Orchard TJ, Saxton JA: Clinically relevant cognitive impairment in middle-aged adults with childhood-onset Type 1 diabetes. *Diabetes Care* 2015, 38:1768-1776.
5. Rawlings AM, Sharrett AR, Schneider AL, Coresh J, Albert M, Couper D, Griswold M, Gottesman RF, Wagenknecht LE, Windham BG, Selvin E: Diabetes in midlife and cognitive change over 20 years: a cohort study. *Ann Intern Med* 2014, 161:785-793.
6. Biessels GJ, Deary IJ, Ryan CM: Cognition and diabetes: a lifespan perspective. *Lancet Neurol* 2008, 7:184-190.
7. Li JQ, Tan L, Wang HF, Tan MS, Tan L, Xu W, Zhao QF, Wang J, Jiang T, Yu JT: Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. *J Neurol Neurosurg Psychiatry* 2016, 87:476-484.
8. Zheng F, Yan L, Yang Z, Zhong B, Xie W: HbA(1c), diabetes and cognitive decline: the English longitudinal study of ageing. *Diabetologia* 2018, 61:839-848.
9. Sink KM, Divers J, Whitlow CT, Palmer ND, Smith SC, Xu J, Hugenschmidt CE, Wagner BC, Williamson JD, Bowden DW, et al: Cerebral structural changes in diabetic kidney disease: African American-Diabetes Heart Study MIND. *Diabetes Care* 2015, 38:206-212.
10. Morris JK, Vidoni ED, Honea RA, Burns JM: Impaired glycemia increases disease progression in mild cognitive impairment. *Neurobiol Aging* 2014, 35:585-589.
11. Zhang DA, Lam V, Chu V, Li M: Type 2 diabetes with comorbid depression in relation to cognitive impairment: an opportunity for prevention? *Mol Neurobiol* 2018, 55:85-89.
12. Nooyens AC, Baan CA, Spijkerman AM, Verschuren WM: Type 2 diabetes and cognitive decline in middle-aged men and women: the Doetinchem Cohort Study. *Diabetes Care* 2010, 33:1964-1969.
13. Hammad SS, Jones PJ: Dietary fatty acid composition modulates obesity and interacts with obesity-related genes. *Lipids* 2017, 52:803-822.
14. Namekawa J, Takagi Y, Wakabayashi K, Nakamura Y, Watanabe A, Nagakubo D, Shirai M, Asai F: Effects of high-fat diet and fructose-rich diet on obesity, dyslipidemia and hyperglycemia in the WBN/Kob-Lepr(fa) rat, a new model of type 2 diabetes mellitus. *J Vet Med Sci* 2017, 79:988-991.
15. Barrière DA, Noll C, Roussy G, Lizotte F, Kessai A, Kirby K, Belleville K, Beaudet N, Longpré JM, Carpentier AC, et al: Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. *Sci Rep* 2018, 8:424.
16. Pimentel GD, Lira FS, Rosa JC, Oliveira JL, Losinkas-Hachul AC, Souza GI, das Graças TdCM, Santos RV, de Mello MT, Tufik S, et al: Intake of trans fatty acids during gestation and lactation leads to hypothalamic inflammation via TLR4/NFκBp65 signaling in adult offspring. *J Nutr Biochem* 2012, 23:265-271.
17. Finucane OM, Lyons CL, Murphy AM, Reynolds CM, Klinger R, Healy NP, Cooke AA, Coll RC, McAllan L, Nilaweera KN, et al: Monounsaturated fatty acid-enriched high-fat diets impede adipose NLRP3 inflammasome-mediated IL-1β secretion and insulin resistance despite obesity. *Diabetes* 2015, 64:2116-2128.
18. Duca FA, Sakar Y, Covasa M: The modulatory role of high fat feeding on gastrointestinal signals in obesity. *J Nutr Biochem* 2013, 24:1663-1677.
19. Fan R, Zhao L, Ding BJ, Xiao R, Ma WW: The association of blood non-esterified fatty acid, saturated fatty acids, and polyunsaturated fatty acids levels with mild cognitive impairment in Chinese population aged 35-64 years: a cross-sectional study. *Nutr Neurosci* 2019:1-13.
20. Mozaffarian D: Saturated fatty acids and type 2 diabetes: more evidence to re-invent dietary guidelines. *Lancet Diabetes Endocrinol* 2014, 2:770-772.
21. Hwang DH, Kim JA, Lee JY: Mechanisms for the activation of Toll-like receptor 2/4 by saturated fatty acids and inhibition by docosahexaenoic acid. *Eur J Pharmacol* 2016, 785:24-35.
22. Gérard P: Gut microbiota and obesity. *Cell Mol Life Sci* 2016, 73:147-162.
23. Cao H, Gerhold K, Mayers JR, Wiest MM, Watkins SM, Hotamisligil GS: Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. *Cell* 2008, 134:933-944.

24. Souza CO, Teixeira AA, Lima EA, Batatinha HA, Gomes LM, Carvalho-Silva M, Mota IT, Streck EL, Hirabara SM, Rosa Neto JC: Palmitoleic acid (n-7) attenuates the immunometabolic disturbances caused by a high-fat diet independently of PPAR α . *Mediators Inflamm* 2014, 2014:582197.
25. Duarte AI, Candeias E, Alves IN, Mena D, Silva DF, Machado NJ, Campos EJ, Santos MS, Oliveira CR, Moreira PI: Liraglutide protects against brain Amyloid- β (1-42) accumulation in female mice with early Alzheimer's disease-like pathology by partially rescuing oxidative/nitrosative stress and inflammation. *Int J Mol Sci* 2020, 21.
26. Lankinen MA, Stančáková A, Uusitupa M, Ågren J, Pihlajamäki J, Kuusisto J, Schwab U, Laakso M: Plasma fatty acids as predictors of glycaemia and type 2 diabetes. *Diabetologia* 2015, 58:2533-2544.
27. Wu JHY, Marklund M, Imamura F, Tintle N, Ardisson Korat AV, de Goede J, Zhou X, Yang WS, de Oliveira Otto MC, Kröger J, et al: Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. *Lancet Diabetes Endocrinol* 2017, 5:965-974.
28. Ding B, Xiao R, Ma W, Zhao L, Bi Y, Zhang Y: The association between macronutrient intake and cognition in individuals aged under 65 in China: a cross-sectional study. *BMJ Open* 2018, 8:e018573.
29. Dong Y, Yean Lee W, Hilal S, Saini M, Wong TY, Chen CL, Venketasubramanian N, Ikram MK: Comparison of the Montreal Cognitive Assessment and the Mini-Mental State Examination in detecting multi-domain mild cognitive impairment in a Chinese sub-sample drawn from a population-based study. *Int Psychogeriatr* 2013, 25:1831-1838.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985, 28:412-419.
31. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000, 85:2402-2410.
32. Li K, Brennan L, McNulty BA, Bloomfield JF, Duff DJ, Devlin NF, Gibney MJ, Flynn A, Walton J, Nugent AP: Plasma fatty acid patterns reflect dietary habits and metabolic health: A cross-sectional study. *Mol Nutr Food Res* 2016, 60:2043-2052.
33. Muthén BO, Muthén LK, Asparouhov T: Regression and mediation analysis using mplus. 2016.
34. Sharma G, Parihar A, Talaiya T, Dubey K, Porwal B, Parihar MS: Cognitive impairments in type 2 diabetes, risk factors and preventive strategies. *J Basic Clin Physiol Pharmacol* 2020, 31.
35. Kahn BB, Flier JS: Obesity and insulin resistance. *J Clin Invest* 2000, 106:473-481.
36. Parvaresh Rizi E, Baig S, Shabeer M, Teo Y, Mok SF, Loh TP, Magkos F, Virtue S, Vidal-Puig A, Tai ES, et al: Meal rich in carbohydrate, but not protein or fat, reveals adverse immunometabolic responses associated with obesity. *Nutr J* 2016, 15:100.
37. McLean FH, Campbell FM, Langston RF, Sergi D, Resch C, Grant C, Morris AC, Mayer CD, Williams LM: A high-fat diet induces rapid changes in the mouse hypothalamic proteome. *Nutr Metab (Lond)* 2019, 16:26.
38. Hou Q, Guan Y, Yu W, Liu X, Wu L, Xiao M, Lü Y: Associations between obesity and cognitive impairment in the Chinese elderly: an observational study. *Clin Interv Aging* 2019, 14:367-373.
39. Allen PJ, Batra P, Geiger BM, Wommack T, Gilhooly C, Pothos EN: Rationale and consequences of reclassifying obesity as an addictive disorder: neurobiology, food environment and social policy perspectives. *Physiol Behav* 2012, 107:126-137.
40. Alosco ML, Gunstad J: The negative effects of obesity and poor glycemic control on cognitive function: a proposed model for possible mechanisms. *Curr Diab Rep* 2014, 14:495.
41. Gardarsdóttir M, Sigurdsson S, Aspelund T, Rokita H, Launer LJ, Gudnason V, Arnar DO: Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. *Europace* 2018, 20:1252-1258.
42. Solfrizzi V, Custodero C, Lozupone M, Imbimbo BP, Valiani V, Agosti P, Schilardi A, D'Introno A, La Montagna M, Calvani M, et al: Relationships of dietary patterns, foods, and micro- and macronutrients with Alzheimer's disease and late-life cognitive disorders: a systematic review. *J Alzheimers Dis* 2017, 59:815-849.
43. Dohrmann DD, Putnik P, Bursać Kovačević D, Simal-Gandara J, Lorenzo JM, Barba FJ: Japanese, Mediterranean and Argentinean diets and their potential roles in neurodegenerative diseases. *Food Res Int* 2019, 120:464-477.
44. Yu H, Bi Y, Ma W, He L, Yuan L, Feng J, Xiao R: Long-term effects of high lipid and high energy diet on serum lipid, brain fatty acid composition, and memory and learning ability in mice. *Int J Dev Neurosci* 2010, 28:271-276.
45. Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, Viitanen M, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M: Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. *Dement Geriatr Cogn Disord* 2006, 22:99-107.
46. Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Torres F, Rizzo C, Capurso A, Panza F: Dietary intake of unsaturated fatty acids and age-related cognitive decline: a 8.5-year follow-up of the Italian Longitudinal Study on Aging. *Neurobiol Aging* 2006, 27:1694-1704.
47. Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D'Onofrio G, Addante F, Sancarolo D, Cascavilla L, Pilotto A, Panza F: Mediterranean diet in predementia and dementia syndromes. *Curr Alzheimer Res* 2011, 8:520-542.
48. MacDonald-Wicks L, McEvoy M, Magennis E, Schofield PW, Patterson AJ, Zacharia K: Dietary long-chain fatty acids and cognitive performance in older Australian adults. *Nutrients* 2019, 11.
49. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D: Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. *Am J Epidemiol* 1997, 145:33-41.
50. Grimble RF, Tappia PS: Modulation of pro-inflammatory cytokine biology by unsaturated fatty acids. *Z Ernährungswiss* 1998, 37 Suppl 1:57-65.

51. Bigornia SJ, Scott TM, Harris WS, Tucker KL: Prospective associations of erythrocyte composition and dietary intake of n-3 and n-6 PUFA with measures of cognitive Function. *Nutrients* 2018, 10.
52. Dong Y, Xu M, Kalueff AV, Song C: Dietary eicosapentaenoic acid normalizes hippocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central interleukin-1 β administration. *Eur J Nutr* 2018, 57:1781-1791.
53. Stavrinou PS, Andreou E, Aphasimis G, Pantzaris M, Ioannou M, Patrikios IS, Giannaki CD: The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment. *Nutrients* 2020, 12.
54. Bonafini S, Giontella A, Tagetti A, Bresadola I, Gaudino R, Cavarzere P, Ramaroli DA, Branz L, Marcon D, Pietrobelli A, et al: Fatty acid profile and desaturase activities in 7-10-year-old children attending primary school in verona south district: association between palmitoleic acid, SCD-16, Indices of adiposity, and blood Pressure. *Int J Mol Sci* 2020, 21.
55. Kopf T, Schaefer HL, Troetzmueller M, Koefeler H, Broenstrup M, Konovalova T, Schmitz G: Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats. *PLoS One* 2014, 9:e106849.
56. Astarita G, Jung KM, Vasilevko V, Dipatrizio NV, Martin SK, Cribbs DH, Head E, Cotman CW, Piomelli D: Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer's disease. *PLoS One* 2011, 6:e24777.
57. Obukowicz M, Welsch D, Salsgiver W, Martin-Berger C, Chinn K, Duffin K, Raz A, Needleman P: Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice. *Lipids* 1999, 34 Suppl:S149.
58. Chawla A, Nguyen KD, Goh YP: Macrophage-mediated inflammation in metabolic disease. *Nat Rev Immunol* 2011, 11:738-749.
59. Donath, Marc Y, Shoelson, Steven E: Type 2 diabetes as an inflammatory disease. *Nature Reviews Immunology* 2011.
60. Dutheil S, Ota KT, Wohleb ES, Rasmussen K, Duman RS: High-fat diet induced anxiety and anhedonia: impact on brain homeostasis and inflammation. *Neuropsychopharmacology* 2016, 41:1874-1887.
61. Tamer F, Ulug E, Akyol A, Nergiz-Unal R: The potential efficacy of dietary fatty acids and fructose induced inflammation and oxidative stress on the insulin signaling and fat accumulation in mice. *Food Chem Toxicol* 2020, 135:110914.
62. Granholm AC, Bimonte-Nelson HA, Moore AB, Nelson ME, Freeman LR, Sambamurti K: Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. *J Alzheimers Dis* 2008, 14:133-145.
63. O'Mahoney LL, Matu J, Price OJ, Birch KM, Ajjan RA, Farrar D, Tapp R, West DJ, Deighton K, Campbell MD: Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. *Cardiovasc Diabetol* 2018, 17:98.
64. Magalhães CA, Carvalho MDG, Sousa LP, Caramelli P, Gomes KB: Alzheimer's disease and cytokine IL-10 gene polymorphisms: is there an association? *Arq Neuropsiquiatr* 2017, 75:649-656.
65. Ouyang W, O'Garra A: IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. *Immunity* 2019, 50:871-891.
66. Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A, Chen Z, Van Waes C, Gursay A, Keskin O, Nussinov R: The structural network of Interleukin-10 and its implications in inflammation and cancer. *BMC Genomics* 2014, 15 Suppl 4:S2.
67. Haygert P, Roversi K, Milanese LH, Maurer LH, Camponogara C, Duarte T, Barcelos RCS, Emanuelli T, Oliveira SM, Duarte M, et al: Can the dietary fat type facilitate memory impairments in adulthood? A comparative study between Mediterranean and Western-based diet in rats. *J Nutr Biochem* 2018, 59:104-113.
68. Guillemot-Legris O, Muccioli GG: Obesity-Induced Neuroinflammation: Beyond the Hypothalamus. *Trends Neurosci* 2017, 40:237-253.
69. Hao S, Dey A, Yu X, Stranahan AM: Dietary obesity reversibly induces synaptic stripping by microglia and impairs hippocampal plasticity. *Brain Behav Immun* 2016, 51:230-239.
70. Zheng M, Chang B, Tian L, Shan C, Chen H, Gao Y, Huang G, Zhang M: Relationship between inflammatory markers and mild cognitive impairment in Chinese patients with type 2 diabetes: a case-control study. *BMC Endocr Disord* 2019, 19:73.
71. Azuma MM, Gomes-Filho JE, Ervolino E, Cardoso CBM, Pipa CB, Kawai T, Conti LC, Cintra LTA: Omega-3 fatty acids reduce inflammation in rat apical periodontitis. *J Endod* 2018, 44:604-608.
72. Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T: AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. *Gene Ther* 2012, 19:724-733.
73. Wennberg AMV, Hagen CE, Machulda MM, Knopman DS, Petersen RC, Mielke MM: The cross-sectional and longitudinal associations between IL-6, IL-10, and TNF α and cognitive outcomes in the mayo clinic study of aging. *J Gerontol A Biol Sci Med Sci* 2019, 74:1289-1295.